Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000737 | 0.94 | MCHR1 (0.53) | MCHR1KCNH2 | |
| SCHEMBL2890423 | 0.90 | MCHR1 (0.58) | MCHR1KCNH2 | |
| SCHEMBL2894302 | 0.87 | MCHR1 (0.65) | MCHR1KCNH2 | |
| SCHEMBL1002062 | 0.85 | MCHR1 (0.53) | MCHR1KCNH2 | |
| SCHEMBL1004382 | 0.85 | MCHR1 (0.55) | MCHR1KCNH2 | |
| SCHEMBL2887173 | 0.83 | MCHR1 (0.59) | MCHR1KCNH2 | |
| SCHEMBL1002911 | 0.82 | MCHR1 (0.52) | MCHR1KCNH2 | |
| SCHEMBL2894224 | 0.82 | MCHR1 (0.52) | MCHR1KCNH2 | |
| SCHEMBL1002254 | 0.81 | MCHR1 (0.51) | MCHR1KCNH2 | |
| SCHEMBL4532298 | 0.81 | MCHR1 (0.56) | MCHR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875633-B2 | 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | MCHR1 439/4885KCNH2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.